President Trump Launches TrumpRx Website to Deliver Lowest Drug Prices in America

A Major Step Forward in Affordable Healthcare

President Donald Trump has taken decisive action to address the high cost of prescription drugs by launching TrumpRx.gov. This new website connects Americans directly with manufacturers offering significant discounts on essential medications. The initiative stems from successful negotiations with major pharmaceutical companies, ensuring prices align with those in other developed nations.

Through most-favored-nation pricing deals, the administration has secured commitments from companies like Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, and EMD Serono. These agreements allow uninsured or cash-paying patients to access drugs at reduced rates, bypassing traditional supply chains that often inflate costs. This move fulfills a key promise to put American patients first and stop subsidizing lower prices abroad.

Details of the Launch Event

On February 5, President Trump unveiled the website during a White House event, joined by Dr. Oz and National Design Studio Director Joe Gebbia. The platform went live with about 40 medications available, focusing on high-demand treatments for conditions like obesity, diabetes, infertility, asthma, and chronic obstructive pulmonary disease.

White House Press Secretary Karoline Leavitt highlighted the significance of the launch in a statement. She described TrumpRx as a state-of-the-art tool that will help millions save on their prescriptions. The event underscored the administration's commitment to practical solutions that benefit everyday Americans facing rising healthcare expenses.

The website's user-friendly design allows patients to search for drugs, obtain coupons for pharmacies, or purchase directly from manufacturers. This direct approach eliminates middlemen, ensuring savings are passed straight to consumers.

Significant Savings on Key Medications

Among the standout offerings are deep discounts on popular weight-loss and diabetes drugs. For instance, Eli Lilly's Zepbound is available starting at $299 per month, down from its list price of $1,088. Novo Nordisk's Wegovy pill starts at $149, a substantial reduction from $1,349. These prices represent average savings of around 70 percent, making life-changing treatments more accessible.

Other notable discounts include fertility medications from EMD Serono. Gonal-F drops to as low as $168 per pen, while Cetrotide falls from $316 to $22.50. Such reductions can save families thousands per treatment cycle, supporting those building their families without financial strain.

Asthma and COPD patients also benefit. AstraZeneca's Bevespi Aerosphere is now $51, down from $458, and Airsupra drops to $201 from $504. Pfizer contributes over 30 medicines with average discounts of 50 percent, up to 85 percent off list prices, including treatments for menopause symptoms and rheumatoid arthritis.

How TrumpRx Benefits American Families

The platform primarily aids the uninsured, who number around 27 million, by providing an alternative to full retail prices. Even insured individuals with high deductibles may find better deals here, especially for drugs not fully covered by plans. The administration encourages users to compare costs with their insurance copays to maximize savings.

President Trump emphasized the transformative impact during the unveiling. 'We’re going to save a lot of money and be healthy,' he stated, promising billions in overall savings. 'You’re going to see numbers that you’re not going to believe.' These words reflect the potential for real relief in household budgets strained by medical expenses.

Building on Successful Negotiations

The foundation of TrumpRx lies in 16 deals with global drugmakers, secured since September 2025. These agreements exempt companies from tariffs in exchange for lower prices to Medicaid and direct consumers. Pfizer was the first, announcing 50 percent average discounts on primary care and specialty drugs.

In November, deals with Eli Lilly and Novo Nordisk expanded Medicare coverage for weight-loss drugs while slashing cash prices. December brought agreements with Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi, adding more options to the portal.

An agreement with the United Kingdom in December increases their drug prices by 25 percent, ensuring fairer global sharing of innovation costs. This comprehensive strategy demonstrates effective leadership in tackling longstanding pricing disparities.

Future Expansions and Legislative Push

More drugs will join the site soon, as additional manufacturers integrate their offerings. The administration is pushing Congress to codify these savings into law through The Great Healthcare Plan, which also aims to lower premiums and enhance transparency.

While experts note the primary benefit to cash payers, the initiative marks a tangible step toward broader affordability. As one analyst observed, it focuses on healthcare accessibility in a meaningful way. With ongoing additions, TrumpRx positions itself as a vital resource for millions seeking relief from high drug costs.